Introduction Auto-immune diseases are complex and heterogeneous. Various types of
biomarkers can be used to support precision medicine approaches to autoimmune …

Tremendous progress has been made over the past decade in the development and
refinement of genomic and proteomic technologies for the identification of novel drug targets …

The use of biomarkers is becoming increasingly intrinsic to the practice of medicine and
holds great promise for transforming the practice of rheumatology. Biomarkers have the …

Highlights•Validated biomarkers for predicting therapy response in autoimmunity are
lacking.•Lack of standardization and independent validation impedes biomarker …

Systemic lupus erythematosus (SLE) is an autoimmune disease that has diverse clinical
manifestations, ranging from restricted cutaneous involvement to life-threatening systemic …

In recent years, biomarkers have shown significant promise in helping decision‐making in
drug development. Systemic lupus erythematosus (SLE) is a complicated and highly …

Current clinical, laboratory or radiological parameters cannot accurately diagnose or predict
disease outcomes in a range of autoimmune disorders. Biomarkers which can diagnose at …

Over the past two decades, the management of rheumatoid arthritis (RA) has progressed
remarkably, encompassing the development of new diagnostic tools and efficacious …

Inter-individual variability has been a major hurdle to optimize disease management.
Precision medicine holds promise for improving health and healthcare via tailor-made …

Better biomarkers, ideally mechanistic ones, are needed to guide clinical decision making in
rheumatology. Although the use of next-generation techniques for biomarker discovery is …